Colorectal News and Research

RSS

Statin use may increase risk of developing benign colorectal tumors: APC trial

Statins did not protect patients against colorectal adenomas, which are benign precursors of colorectal cancer, according to results of a secondary analysis of the Adenoma Prevention with Celecoxib trial. In a population at high-risk for developing these lesions, results of this analysis suggested statin use may increase the risk of developing benign colorectal tumors.

20 Apr 2010

UAB researchers discover four miRNAs to assess survival rate of colorectal cancer patients

Researchers at the University of Alabama at Birmingham Department of Pathology have discovered a set of four biomarkers that will help predict which patients are more likely to develop aggressive colorectal cancer and which are not. The findings also shed light on the genetics that result in worse colorectal cancer-treatment outcomes for African-Americans, compared with Caucasians, the researchers said.

20 Apr 2010

Exact Sciences completes 4.2M share common stock public offering

Exact Sciences Corp. announced today that it has completed its previously announced underwritten public offering of 4.2 million shares of common stock at a price of $4.50 per share to the public.

20 Apr 2010

New research shows link between infection-related diseases and risk of cancer

New research is emerging that suggests a link between infection-related diseases and risk of cancer, according to findings presented here at the American Association for Cancer Research 101st Annual Meeting 2010.

20 Apr 2010

Biomarkers to help predict development of aggressive colorectal cancer discovered

Researchers at the University of Alabama at Birmingham (UAB) Department of Pathology have discovered a set of four biomarkers that will help predict which patients are more likely to develop aggressive colorectal cancer and which are not. The findings also shed light on the genetics that result in worse colorectal cancer-treatment outcomes for African-Americans, compared with Caucasians, the researchers said.

19 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

Study reveals increased risk for cancer among Latino populations

New findings from epidemiology and observational studies show an increased risk for cancer among Latino populations, but unique demographic characteristics suggest the problem may be worse than currently known.

19 Apr 2010

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.

19 Apr 2010

Debate continues over prostate cancer screening in Europe

The European Association of Urology reiterated that it does not recommend a mass screening policy in Europe for men who are concerned over prostate cancer, a stance which reflects the position it issued last year regarding prostate cancer screening. "We don't believe that the time has come for mass screening," said EAU Secretary General.

19 Apr 2010

MedImmune to present ten abstracts at American Association for Cancer Research meeting

MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

17 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

Low income and lack of health insurance result in fewer rate of colorectal cancer screening

High out-of-pocket costs, lack of health insurance and limited access to care contribute to a relatively low rate of colorectal cancer screening in the United States, according to a new systematic review by researchers at the RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center.

16 Apr 2010

Current screening methods for FOBT are often not appropriate

More than 75 percent of primary care physicians in the United States who order or perform the fecal occult blood test as a screening option for colorectal cancer perform an in-office test rather than relying on the home-based test, even though the home-based test is more accurate, a study by the Centers for Disease Control and Prevention has found.

16 Apr 2010

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that it has completed patient enrollment in a Phase 1 clinical trial evaluating the intravenous (IV) administration of JX-594, the company's lead product for the treatment of solid tumors. Jennerex expects to report the results from this trial at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2010.

15 Apr 2010

Inflammasome components help protect against colitis

Particular components of inflammasomes-protein complexes needed for generating immune responses to pathogens and cellular damage-lessen the severity of colitis and colitis-associated colon cancer in mice, according to a study published online this week in the Journal of Experimental Medicine.

13 Apr 2010

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

Scientific breakthroughs in molecular targeting, translational cancer research and cancer prevention will take center stage when more than 17,000 scientists from around the world gather at the Walter E. Washington Convention Center, April 17-21, for the AACR 101st Annual Meeting 2010.

13 Apr 2010

SAGES 2010: Covidien to showcase technological advancements in bariatric, colorectal and hernia surgery

Covidien, a leading global provider of healthcare products, will preview a variety of new devices and showcase some of the Company's most innovative tools for endoscopic surgery and soft tissue repair at the 2010 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting held here.

13 Apr 2010

Study explains why Hispanics are less likely to undergo colorectal cancer screening

A new study finds that Hispanics live in areas with more limited availability of colonoscopies and sigmoidoscopies for colorectal cancer screening. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that differences in areas' capacity for providing these procedures may explain why Hispanics are less likely to undergo colorectal cancer screening than non-Hispanic whites.

12 Apr 2010

Colorectal News and Research

Statin use may increase risk of developing benign colorectal tumors: APC trial

UAB researchers discover four miRNAs to assess survival rate of colorectal cancer patients

Exact Sciences completes 4.2M share common stock public offering

New research shows link between infection-related diseases and risk of cancer

Biomarkers to help predict development of aggressive colorectal cancer discovered

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

Study reveals increased risk for cancer among Latino populations

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Debate continues over prostate cancer screening in Europe

MedImmune to present ten abstracts at American Association for Cancer Research meeting

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Low income and lack of health insurance result in fewer rate of colorectal cancer screening

Current screening methods for FOBT are often not appropriate

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Inflammasome components help protect against colitis

Over 17,000 scientists convene at AACR 101st Annual Meeting 2010

SAGES 2010: Covidien to showcase technological advancements in bariatric, colorectal and hernia surgery

Study explains why Hispanics are less likely to undergo colorectal cancer screening

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News